Viemed Healthcare, Inc. (VMD) Guidance & Earnings Results

On 2026-08-03 Viemed Healthcare, Inc. raised guidance: "FY revenue raised to $314M-$320M from $312M-$320M; adj EBITDA revised to $64M-$68M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VMDViemed Healthcare, Inc.Follow VMD — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 373.3M
P/E TTM: 27.2
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
3 Aug 26	Raised	FY revenue raised to $314M-$320M from $312M-$320M; adj EBITDA revised to $64M-$68M from $65M-$69M · full year
5 May 26	Raised	Revenue guidance raised to $312M-$320M from $310M-$320M; Adj. EBITDA reaffirmed $65M-$69M; capex guidance lowered to 9%-10.5% from 10%-11.5% · full year
4 Mar 26	Raised	FY2026 revenue guidance $310-320M; Adjusted EBITDA $65-69M · full year
5 Nov 25	Raised	Adjusted EBITDA guidance raised to $60-62M from $59-62M; revenue guidance narrowed to $271-273M · full year
6 Aug 25	Raised	FY2025 revenue raised to $271-277M from $256-265M; FY2025 adjusted EBITDA raised to $59-62M from $55-58M · full year

Viemed Healthcare, Inc. — questions

What guidance did Viemed Healthcare, Inc. give?: On 2026-08-03: "FY revenue raised to $314M-$320M from $312M-$320M; adj EBITDA revised to $64M-$68M from $65M-$69M"
When does Viemed Healthcare, Inc. report earnings?: Viemed Healthcare, Inc.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from Viemed Healthcare, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.